MedTrace Logo

Liposomal Doxorubicin and Carboplatin in Treating Patients With Gynecologic Cancer

NCT00032162 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 63

Last updated 2012-05-31

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.

PURPOSE: Phase I/II trial to study the effectiveness of combining liposomal doxorubicin with carboplatin in treating patients who have gynecologic cancer.

Conditions

Interventions

DRUG

carboplatin

AUC 6 q4w

DRUG

pegylated liposomal doxorubicin hydrochloride

20/30/40 mg/qm q4w Dose finding study

Sponsors & Collaborators

  • AGO Study Group

    lead OTHER

Principal Investigators

  • Andreas du Bois, MD, PhD · Dr. Horst-Schmidt-Kliniken

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-08-31
Primary Completion
2005-05-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00032162 on ClinicalTrials.gov